Pizza G, De Vinci C, Fornarola V, Palareti A, Baricordi O, Viza D
Immunodiagnosis and Immunotherapy Unit, S. Orsola Malpighi Hospital, Bologna, Italy.
Biotherapy. 1996;9(1-3):175-85. doi: 10.1007/BF02628677.
153 patients suffering from recurrent pathologies, i.e. viral infections (keratitis, keratouveitis, genital and labial herpes) uveitis, cystitis, and candidiasis were treated with in vitro produced transfer factor (TF) specific for HSV-1/2, CMV and Candida albicans. The cell-mediated immunity of seropositive patients to HSV-1/2 and/or CMV viruses was assessed using the leucocyte migration inhibition test (LMT) and lymphocyte stimulation test (LST) in presence of the corresponding antigens, and the frequency of positive tests before, during and after TF administration was studied. The data were stratified per type of test, antigen and the recipients' pathology, and statistically evaluated. For the LMT, a total of 960 tests were carried out for each antigen dilution, 3 different antigen dilutions were used per test. 240/960 tests (25.4%) were found positive during non-treatment or treatment with unspecific TF, whereas 147/346 tests (42.5%) were found positive when the antigen corresponding to the specificity of the TF administered to the patient was used (P < 0.001). When the data were stratified following pathology, a significant increased incidence of positive tests during specific treatment was also observed (0.0001 < P < 0.05). In the LST (1174 tests), a significant increase of thymidine uptake was observed in the absence of antigen (control cultures), during treatment with both specific and unspecific TF, but also in the presence of antigen and/or autologous serum during specific TF administration (P < 0.0001). TF administration also significantly increased the soluble HLA class I antigens level in 40 patients studied to this effect.
153例患有复发性疾病的患者，即病毒感染（角膜炎、角膜葡萄膜炎、生殖器和唇疱疹）、葡萄膜炎、膀胱炎和念珠菌病，接受了体外产生的针对单纯疱疹病毒1/2型（HSV-1/2）、巨细胞病毒（CMV）和白色念珠菌的转移因子（TF）治疗。使用白细胞迁移抑制试验（LMT）和淋巴细胞刺激试验（LST），在相应抗原存在的情况下，评估血清阳性患者对HSV-1/2和/或CMV病毒的细胞介导免疫，并研究在给予TF之前、期间和之后阳性试验的频率。数据按试验类型、抗原和接受者的病理情况进行分层，并进行统计学评估。对于LMT，每种抗原稀释度共进行960次试验，每次试验使用3种不同的抗原稀释度。在未治疗或使用非特异性TF治疗期间，240/960次试验（25.4%）呈阳性，而当使用与给予患者的TF特异性对应的抗原时，147/346次试验（42.5%）呈阳性（P<0.001）。当按病理情况对数据进行分层时，在特异性治疗期间阳性试验的发生率也显著增加（0.0001<P<0.05）。在LST（1174次试验）中，在无抗原（对照培养物）的情况下、在使用特异性和非特异性TF治疗期间，以及在特异性TF给药期间存在抗原和/或自体血清的情况下，均观察到胸腺嘧啶摄取显著增加（P<0.0001）。为研究此效果，对40例患者给予TF后，可溶性HLA I类抗原水平也显著升高。
